<?xml version="1.0" encoding="UTF-8"?>
<p id="p0040">In a pandemic, there are inherent challenges to conducting randomized, controlled trials (RCTs) with the urgent need to decrease mortality. Treatment based on preliminary science has ethical implications, and in many cases, the opportunity to rigorously study treatments before the pandemic subsides is lost. The rigor of scientific evidence for clinical benefit must be balanced with the expediency of treatment need.</p>
